Turn Biotechnologies Email Format
Biotechnology ResearchCalifornia, United States11-50 Employees
Turn Biotechnologies is a biotechnology research company based at 319 North Bernardo Avenue, Mountain View, California 94043, United States, with 11-50 employees. The company develops a transient reprogramming therapy intended to rejuvenate aging cells, aiming to address multiple aging-related indications by reversing eight of the nine hallmarks of aging identified in a Cell paper. It has pursued licensing and collaboration efforts, including an exclusive license with HanAll Biopharma to develop Epigenetic Reprogramming of Aging (ERA) technology for ophthalmic and otic diseases. In September 2025, Turn Biotechnologies sold assets to Klotho Neurosciences for $300 million, and Klotho Neurosciences signed a letter of intent to acquire select assets from Turn Biotechnologies, anchored by a $300 million global pharma partnership. The company launched eTurna, a delivery platform for nucleic acid therapeutics, in September 2022, and maintains a website at turn.bio.